Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
32.02
-0.44 (-1.36%)
At close: Dec 5, 2025, 4:00 PM EST
32.00
-0.02 (-0.06%)
After-hours: Dec 5, 2025, 6:05 PM EST
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Viridian Therapeutics stock have an average target of 39, with a low estimate of 26 and a high estimate of 61. The average target predicts an increase of 21.80% from the current stock price of 32.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 6 | 5 |
| Buy | 6 | 5 | 5 | 5 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | +28.04% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +40.54% | Nov 6, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $61 | Strong Buy | Reiterates | $61 | +90.51% | Nov 4, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | +12.43% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
80.26M
from 302.00K
Increased by 26,477.48%
Revenue Next Year
85.26M
from 80.26M
Increased by 6.23%
EPS This Year
-4.15
from -3.07
EPS Next Year
-3.89
from -4.15
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 132.0M | 217.7M | ||||
| Avg | 80.3M | 85.3M | ||||
| Low | 289,100 | 2.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 43,608.6% | 171.2% | ||||
| Avg | 26,477.5% | 6.2% | ||||
| Low | -4.3% | -96.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.52 | -2.45 | ||||
| Avg | -4.15 | -3.89 | ||||
| Low | -4.66 | -4.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.